Speaker
Shardae Showell, PhD
MEDICAL DIRECTOR, CLINICAL DEVELOPMENT, ALZHEIMER’S & DEMENTIA UNIT, BIOGEN
Shardae Showell, Ph.D., is a neuroscientist with over 10 years of expertise in Alzheimer’s disease currently serving as a Medical Director in Clinical Development at Biogen. She began her career in patient care as a critical care technician, supporting patients with neurological disorders. She later shifted from patient care to Alzheimer’s disease research, where she led, and co-designed interventions aimed at addressing cardiovascular risks to Alzheimer’s disease.
Following, Dr. Showell served as an Assistant Professor of Anatomy & Physiology, where her research focused on genetic and social determinants of Alzheimer’s disease. Driven by a desire to advance therapeutic solutions for Alzheimer’s disease, Dr. Showell transitioned into the pharmaceutical industry. Under the support of Gantenerumab in medical affairs, she collaborated with key medical experts to further the understanding of the patient journey, from diagnosis to treatment.
Dr. Showell’s diverse experiences in patient care, research, and medical affairs equipped her with valuable insights to advance her career in drug development. Previously, she supported the Aducanumab program, publishing research on the impact of comorbidities and education on clinical trial participation in underrepresented populations.
Currently, Dr. Showell serves as a Medical Director for supporting Lecanemab and the Health Equity Advisor for clinical development.
Following, Dr. Showell served as an Assistant Professor of Anatomy & Physiology, where her research focused on genetic and social determinants of Alzheimer’s disease. Driven by a desire to advance therapeutic solutions for Alzheimer’s disease, Dr. Showell transitioned into the pharmaceutical industry. Under the support of Gantenerumab in medical affairs, she collaborated with key medical experts to further the understanding of the patient journey, from diagnosis to treatment.
Dr. Showell’s diverse experiences in patient care, research, and medical affairs equipped her with valuable insights to advance her career in drug development. Previously, she supported the Aducanumab program, publishing research on the impact of comorbidities and education on clinical trial participation in underrepresented populations.
Currently, Dr. Showell serves as a Medical Director for supporting Lecanemab and the Health Equity Advisor for clinical development.
Speaking In
11:20 AM - 12:30 PM
Tuesday, November 19